Department of Hematology, Ruijin Hospital, Shanghai Institute of Hematology, Shanghai Jiao-Tong University School of Medicine, Shanghai 200025, China.
J Exp Clin Cancer Res. 2010 Mar 3;29(1):20. doi: 10.1186/1756-9966-29-20.
To retrospectively review the incidence, treatment efficacy, we followed up newly diagnosed chronic myelogenous leukemia (CML) patients residing in Shanghai during 2001-2006.
All eligible cases were reviewed with the data of efficacy responses as well as overall survival (OS) and progression-free survival (PFS) time.
A total of 615 cases entered the study. CML mainly afflicted those aged 40-60 years old and was slightly more frequent in males than females. More than 85% of the patients were in chronic phase (CP) when diagnosed. All patients were divided into four groups based on the main regimens - hydroxyurea, interferon alpha (IFN-alpha), imatinib, and hemopoietic stem cell transplantation (HSCT). With the median follow-up of 18 months, imatinib treatment induced 92.2% complete hematologic responses, and 64.3% complete cytogenetic responses among CML-CP patients. Overall the therapeutic efficacy in the imatinib group was higher than that in the hydroxyurea or IFN-alpha group. Meanwhile, in the imatinib group, all response rates of patients in CP were significantly greater than that in accelerated or blastic crisis phase. The patients treated with imatinib also showed the most promising results regarding OS and PFS. Patients receiving HSCT decreased markedly in number with the introduction of imatinib.
The number of new patients arising in Shanghai increased from 2001 to 2006. There were still patients receiving hydroxyurea and IFN-alpha. As the first-line regime for CML, imatinib was less administered in Shanghai before, but has received considerable development and great responses since 2003.
回顾性分析 2001-2006 年期间上海新诊断的慢性髓系白血病（CML）患者的发病率、治疗效果。
对所有符合条件的病例进行了疗效反应以及总生存（OS）和无进展生存（PFS）时间的回顾。
共有 615 例患者进入研究。CML 主要影响 40-60 岁的人群，男性略多于女性。诊断时超过 85%的患者处于慢性期（CP）。根据主要治疗方案，所有患者分为羟脲、干扰素-α（IFN-α）、伊马替尼和造血干细胞移植（HSCT）4 组。中位随访 18 个月，伊马替尼治疗诱导 CML-CP 患者 92.2%完全血液学反应，64.3%完全细胞遗传学反应。总体而言，伊马替尼组的治疗效果高于羟脲或 IFN-α组。同时，在伊马替尼组中，CP 期患者的所有反应率均明显高于加速期或急变期患者。接受伊马替尼治疗的患者在 OS 和 PFS 方面也表现出最有希望的结果。随着伊马替尼的引入，接受 HSCT 的患者数量显著减少。
上海新发病例数从 2001 年到 2006 年增加。仍有患者接受羟脲和 IFN-α治疗。作为 CML 的一线治疗方案，伊马替尼在上海之前应用较少，但自 2003 年以来得到了相当大的发展和良好的反应。
